[HTML][HTML] Hereditary prostate cancer: genes related, target therapy and prevention

MT Vietri, G D'elia, G Caliendo, M Resse… - International journal of …, 2021 - mdpi.com
Prostate cancer (PCa) is globally the second most diagnosed cancer type and the most
common cause of cancer-related deaths in men. Family history of PCa, hereditary breast …

[HTML][HTML] Cost-of-illness studies: concepts, scopes, and methods

C Jo - Clinical and molecular hepatology, 2014 - ncbi.nlm.nih.gov
Liver diseases are one of the main causes of death, and their ever-increasing prevalence is
threatening to cause significant damage both to individuals and society as a whole. This …

[HTML][HTML] Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges

B Trujillo, A Wu, D Wetterskog, G Attard - British journal of cancer, 2022 - nature.com
Liquid biopsy has been established as a powerful, minimally invasive, tool to detect clinically
actionable aberrations across numerous cancer types in real-time. With the development of …

[HTML][HTML] A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation

J West, F Adler, J Gallaher, M Strobl, R Brady-Nicholls… - Elife, 2023 - elifesciences.org
Adaptive therapy is a dynamic cancer treatment protocol that updates (or 'adapts') treatment
decisions in anticipation of evolving tumor dynamics. This broad term encompasses many …

[HTML][HTML] Clinical validation of a next-generation sequencing-based multi-cancer early detection “liquid biopsy” blood test in over 1,000 dogs using an independent …

A Flory, KM Kruglyak, JA Tynan, LM McLennan… - PLoS …, 2022 - journals.plos.org
Cancer is the leading cause of death in dogs, yet there are no established screening
paradigms for early detection. Liquid biopsy methods that interrogate cancer-derived …

[HTML][HTML] The Lancet Commission on prostate cancer: planning for the surge in cases

ND James, I Tannock, J N'Dow, F Feng, S Gillessen… - The Lancet, 2024 - thelancet.com
Executive summary Prostate cancer is the most common cancer in men in 112 countries,
and accounts for 15% of cancers. In this Commission, we report projections of prostate …

[HTML][HTML] Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer

I Casanova-Salas, A Athie, PC Boutros, M Del Re… - European urology, 2021 - Elsevier
Context Genomic stratification can impact prostate cancer (PC) care through diagnostic,
prognostic, and predictive biomarkers that aid in clinical decision-making. The temporal and …

[HTML][HTML] Liquid biopsies beyond mutation calling: genomic and epigenomic features of cell-free DNA in cancer

AK Angeles, F Janke, S Bauer, P Christopoulos… - Cancers, 2021 - mdpi.com
Simple Summary Liquid biopsies provide a non-invasive means to diagnose and profile
tumors when tissue is not available. Sequence-based analysis of cell-free DNA (cfDNA) is …

[HTML][HTML] Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression

E Lau, P McCoy, F Reeves, K Chow, M Clarkson… - Genome medicine, 2020 - Springer
Background DNA originating from degenerate tumour cells can be detected in the circulation
in many tumour types, where it can be used as a marker of disease burden as well as to …

[HTML][HTML] Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA

JD Finkle, H Boulos, TM Driessen, C Lo… - NPJ Precision …, 2021 - nature.com
Liquid biopsy is a valuable precision oncology tool that is increasingly used as a non-
invasive approach to identify biomarkers, detect resistance mutations, monitor disease …